Literature DB >> 17005304

Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population.

Pamela Rendi-Wagner1, Maria Korinek, Birgit Winkler, Michael Kundi, Herwig Kollaritsch, Ursula Wiedermann.   

Abstract

Hepatitis A vaccines have been demonstrated to be highly immunogenic. Mathematical models have predicted antibodies to persist for at least 20-25 years. Most of these studies have been conducted in young and healthy study populations. We aimed to evaluate long-term immunity 10 years following complete primary immunization according to a 3-dose schedule (Havrix 720 El.U at months 0, 1, 6-12) in an adult and unselected study population. In total, 999 (98.3%) of 1016 vaccinees (mean age 54.7+/-S.D. 13.0), tested 10 years after primary vaccination, still had protective antibody levels (> or = 10 mIU/ml) as measured by ELISA. An anti-HAV titer cut off level of 11,400 mIU/ml was calculated to differentiate between vaccine-induced and infection-induced titer levels. The vaccine-induced geometric mean titer (GMT) was 406.1 mIU/ml (95% CI: 369.2-446.7 mIU/ml), showing an age-related trend, the 10-years seroprotection rate (SPR) was 97.9%. Females exhibited significantly higher GMTs than male vaccinees (p<0.001). The only parameter predicting a titer below 10 mIU/ml 10 years after vaccination was the body mass index (p=0.001). This study confirms that protection following primary hepatitis A vaccination persists for more than 10 years.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005304     DOI: 10.1016/j.vaccine.2006.08.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  [Medical clearance for missions abroad (EEU): definitions, recommendations for use and performance].

Authors:  Herwig Kollaritsch; Christoph Wenisch; Christoph Hatz; Gunther von Laer; Bernd Bauer; Ursula Hollenstein; Martin Haditsch; Gerhard Diridl; Waldemar Malinowski; Eva Jeschko; Gabriela Payer-Neundlinger; Nicole Speiser-Remp; Hannes E T Pichler; Helmut Rumpold; Heinrich Stemberger; Gerald Eder; Gerhard Wiedermann; Ursula Wiedermann
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  [Traveling with immunosuppression].

Authors:  G Birkenfeld
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

3.  A Potent anti-Simian Immunodeficiency Virus Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Rhesus Macaques.

Authors:  Saori Matsuoka; Takeo Kuwata; Hiroshi Ishii; Tsuyoshi Sekizuka; Makoto Kuroda; Masato Sano; Midori Okazaki; Hiroyuki Yamamoto; Mikiko Shimizu; Shuzo Matsushita; Yohei Seki; Akatsuki Saito; Hiromi Sakawaki; Vanessa M Hirsch; Tomoyuki Miura; Hirofumi Akari; Tetsuro Matano
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

4.  Successful Vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Curr Top Microbiol Immunol       Date:  2018-07-26       Impact factor: 4.291

5.  A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults.

Authors:  Olivier Van Der Meeren; Priya Crasta; Marc de Ridder
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination.

Authors:  Erika Garner-Spitzer; Eva-Maria Poellabauer; Angelika Wagner; Angela Guzek; Ines Zwazl; Claudia Seidl-Friedrich; Christoph J Binder; Karin Stiasny; Michael Kundi; Ursula Wiedermann
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

Review 7.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

8.  Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection.

Authors:  Yuto Nomura; Saori Matsuoka; Midori Okazaki; Takeo Kuwata; Tetsuro Matano; Hiroshi Ishii
Journal:  Viruses       Date:  2021-06-21       Impact factor: 5.048

Review 9.  Primary vaccine failure to routine vaccines: Why and what to do?

Authors:  Ursula Wiedermann; Erika Garner-Spitzer; Angelika Wagner
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.